Navigation Links
Leukemia drug found to stimulate immunity against many cancer types
Date:6/11/2014

A class of drug currently being used to treat leukaemia has the unexpected side-effect of boosting immune responses against many different cancers, reports a new study led by scientists at UCL (University College London) and the Babraham Institute, Cambridge.

The drugs, called p110δ inhibitors, have shown such remarkable efficacy against certain leukaemias in recent clinical trials that patients on the placebo were switched to the real drug. Until now, however, they have not been tested in other types of cancer.

The new study, published in Nature, provides the first evidence that such drugs can significantly restrict tumour growth and spread and reduce the chances of relapse for a broad range of cancers. The researchers at UCL, the Babraham Institute and Queen Mary University of London, together with scientists from Genentech, South San Francisco, showed that inhibition of the p110δ enzyme helps to boost the body's immune system to kill tumour cells. The research was funded by Cancer Research UK, the Biotechnology and Biological Sciences Research Council and the Wellcome Trust.

"Our study shows that p110δ inhibitors have the potential to offer effective immunity to many types of cancer by unleashing the body's own immune response," says study co-leader Professor Bart Vanhaesebroeck of the UCL Cancer Institute, who first discovered the p110δ enzyme in 1997. "p110δ is highly expressed and important in white blood cells, called 'leukocytes'. Given that leukaemias are the result of leukocytes becoming cancerous, they are a natural target for p110δ inhibitors. Now, we have shown that blocking p110δ also has the remarkable effect of boosting the body's immune response against leukaemias as well as other cancers."

The team showed that inhibiting p110δ in mice significantly increased cancer survival rates across a broad range of tumour types, both solid and haematological cancers. For example, mice in which p110δ was blocked survived breast cancer for almost twice as long as mice with active p110δ. Their cancers also spread significantly less, with far fewer and smaller tumours developing. Survival after surgical removal of primary breast cancer tumours was also vastly improved, which has important clinical implications for stopping breast cancer from returning following surgery. The team's data further show that following p110δ inhibition, the immune system could develop an effective memory response to completely fight off the cancer.

Lead author Dr Khaled Ali, who is now based at Amgen, San Francisco, says: "When we first introduced tumours in p110δ-deficient mice, we expected them to grow faster because p110δ is important for the immune system. Instead, some tumours started shrinking. When we investigated this unexpected effect, we found that p110δ is especially important in so-called regulatory T cells which are suppressive immune cells that the tumours engage to protect themselves against immune attack."

The p110δ enzyme is a member of the PI3-kinase family, and is sometimes called PI3Kδ. p110δ and the other PI3Ks are hot drug targets for the pharmaceutical industry as they are implicated in many cancers and are readily druggable.

"Our work shows that p110δ inhibitors can shift the balance from the cancer becoming immune to our body's defences towards the body becoming immune to the cancer, by disabling regulatory T cells," says study co-leader Dr Klaus Okkenhaug of the Babraham Institute. "This provides a rationale for using these drugs against both solid and blood cancers, possibly alongside cancer vaccines, cell therapies and other treatments that further promote tumour-specific immune responses."

Professor Nic Jones, Cancer Research UK's chief scientist and director of the Manchester Cancer Research Centre, said: "Treatments that train the immune system to recognise and kill cancer cells are showing huge promise in several types of cancer. This new finding, although only at an early stage, offers the potential to develop more treatments that can do this in many more cancers, including ones that have real need for more effective treatments such as pancreatic cancer.

"If the findings hold true in cancer patients this could make a big difference to many of them. The good news is that because the drugs used in this study are already being used in the clinic, we could see rapid translation of this research into patient benefit."


'/>"/>
Contact: Harry Dayantis
h.dayantis@ucl.ac.uk
44-020-310-83844
University College London
Source:Eurekalert

Related medicine news :

1. One in 4 children with leukemia not taking maintenance medication, study shows
2. Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia
3. Tiny mutation triggers drug resistance for patients with one type of leukemia
4. Major discovery on the mechanism of drug resistance in leukemia and other cancers
5. New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
6. Novel target found for chemotherapy-resistant leukemia cells
7. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
8. A gene within a gene contributes to the aggressiveness of acute myeloid leukemia
9. Experimental drug shows promise for treatment-resistant leukemias
10. Chemo-free treatment a possibility for leukemia/lymphoma
11. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 22, 2017 , ... The Burke Medical Research Institute (BMRI) ... in basic neuroscience at the BMRI labs into new and improved treatments for ... vision, and cognition impaired by stroke, traumatic brain injury, cerebral palsy, and birth ...
(Date:3/22/2017)... VA (PRWEB) , ... March 22, 2017 , ... ... asset protection assistance and financial consultations to families and business owners in the ... support for the local American Cancer Society Relay For Life event. , Each ...
(Date:3/22/2017)... ... ... Schneider Insurance and Financial, a southern Montana firm providing asset protection and financial ... a charity event aimed at raising local support for Zoo Montana. , Zoo Montana ... home to a broad variety of animals from all over the world. Many of ...
(Date:3/22/2017)... ... March 22, 2017 , ... College basketball surges to its peak ... for recruiting – that is, recruiting people to be foster parents. Through a televised ... who are in foster care due to abuse, neglect and other family challenges. People ...
(Date:3/22/2017)... ... March 22, 2017 , ... NYC Chiropractor Dr. Steven ... was the first of its kind in the U.S. and focused on a new ... Amino BioFrequency Therapy to New York, and furthermore the first seminar in ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... March 22, 2017 EMD Serono, the biopharmaceutical business ... the U.S. and Canada , today announced ... poster presentation session at the 65 th Annual Pacific ... California on March 24 th .   ... real-world database collected from July 2009 to December 2015 containing ...
(Date:3/22/2017)... , March 22, 2017  Levine Cancer ... tomography (CT) unit designed to address lung cancer ... across the Carolinas. The mobile lung unit is ... cancer education and treatment interventions through integrated mobile ... Financial barriers and a lack of ...
(Date:3/22/2017)... SANTA CLARA, Calif. , March 22, 2017 ... diagnostic cardiology  solutions segment, Frost & Sullivan recognizes ... Sullivan Company of the Year Award. GE Healthcare,s ... offer end-to-end cardiac solutions has allowed it to ... competitive cardiac monitoring products space. In addition to ...
Breaking Medicine Technology: